2024
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.Peer-Reviewed Original ResearchSmall cell bladder cancerConcurrent chemoradiotherapyNeoadjuvant chemotherapySEER-Medicare databaseMedian OSLocoregional therapySEER-MedicareBladder cancerHistological subtypesOverall survivalInstitutional databaseCompare outcomesOptimal locoregional therapyAggressive histologic subtypeNon-metastatic stageNon-metastatic diseaseSEER-Medicare datasetMultivariate Cox analysisFollow-up/deathLocalized diseaseCox analysisCystectomyTreatment patternsTreatment responseMultivariate analysisPatterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older
Ghali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Grivas P, Hawley J, Hsieh A, Montgomery R, Wright J. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Frontiers In Oncology 2024, 14: 1341655. PMID: 38812783, PMCID: PMC11133586, DOI: 10.3389/fonc.2024.1341655.Peer-Reviewed Original ResearchMuscle invasive bladder cancerPatterns of chemotherapy useRadiation therapyReceipt of chemotherapyChemotherapy useMultivariate logistic regressionConcurrent chemotherapyOverall survivalBladder cancerFactors associated with receipt of chemotherapyMaximum transurethral resection of bladder tumorNational Cancer Institute comorbidity indexTransurethral resection of bladder tumorAlternative to radical cystectomyAssociated with superior OSReceipt of concurrent chemotherapyResection of bladder tumorCurative-intent RTLow dose gemcitabineUtilization of chemotherapyLocalized bladder cancerInvasive bladder cancerFactors associated with receiptYear of diagnosisSuperior disease controlAdjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.Peer-Reviewed Original ResearchNational Cancer DatabaseAdjuvant chemotherapyReceipt of ACRadical cystectomyBladder cancerOverall survivalAssociated with significantly longer OSAssociated with OS benefitNon-metastatic bladder cancerMultivariate Cox regression analysisPrevalence of adenocarcinomaSquamous cell histologyMultivariate Cox regressionCox regression analysisMultivariate logistic regressionAssociated with lower oddsAssociated with greater oddsNeuroendocrine histologyLonger OSOS benefitCell histologyHistological subtypesCancer DatabaseClinicopathological featuresCox regression
2023
The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities
Ghali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.Peer-Reviewed Original Research
2022
PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS?
Ghali F, Roudier M, Vakar-Lopez F, Garcia J, Wang Y, Ha G, Grivas P, Lee J, Yu E, Montgomery B, Hsieh A, Wright J, Lam H. PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS? Journal Of Urology 2022, 207: e913. DOI: 10.1097/ju.0000000000002630.09.Peer-Reviewed Original Research